Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025Alvelestat granted ...
Grew ARR 29% year-over-year to $877 millionExpanded SaaS ARR 39% year-over-year to $540 millionFinished the year with an ~80% year-over-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback